Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

• Type of Material: Article
• Authors: Gilles Salles, University Claude Bernard; Stephen J. Schuster, University of Pennsylvania; Sven de Vos, David Geffen School of Medicine at UCLA; Nina D. Wagner-Johnston, Johns Hopkins University; Andreas Viardot, University Hospital of Ulm; Kristie Blum, Emory University; Christopher Flowers, Emory University; Wojciech J. Jurczak, Jagiellonian University; Ian W. Flinn, Sarah Cannon Research Institute; Brad S. Kahl, Washington University School of Medicine; Peter Martin, Weill Cornell Medical College; Yeonhee Kim, Gilead Sciences Inc.; Sanatan Shreay, Gilead Sciences Inc.; MAtthias Will, Gilead Sciences Inc.; Bess Sorensen, Gilead Sciences Inc.; Madlaina Breuleux, Gilead Sciences Inc.; Pier Luigi Zinzani, University of Bologna; Ajay K. Gopal, University of Washington
• Language: English
• Date: 2017-04-01
• Publisher: Ferrata Storti Foundation
• Publication Version: Final Published Version
• Copyright Statement: © 2017 Ferrata Storti Foundation
• Final Published Version (URL): http://dx.doi.org/10.3324/haematol.2016.151738
• Title of Journal or Parent Work: Haematologica
• ISSN: 0390-6078
• Volume: 102
• Issue: 4
• Start Page: E156
• End Page: E159
• Grant/Funding Information: This study was supported by Gilead Sciences, Inc. Editorial assistance for the development of this manuscript was provided by Meryl Gersh, PhD, of AlphaBioCom, LLC, King of Prussia, PA, and funded by Gilead Sciences, Inc., Foster City, CA.
• Keywords: UNITED-STATES; MULTICENTER; Science & Technology; NON-HODGKINS-LYMPHOMA; INDOLENT LYMPHOMA; Life Sciences & Biomedicine; SURVIVAL; Hematology
• Research Categories: Health Sciences, General; Health Sciences, Oncology